Alzheimer's disease failed clinical trials

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works

2020 Alzheimer's disease facts and figures

(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353 · see citing works

The cholinergic hypothesis of Alzheimer’s disease: A review of progress

Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · see citing works

Amyloid Precursor Protein Processing and Alzheimer's Disease

O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · see citing works

Alzheimer's Disease and the Amyloid-β Peptide

Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750 · see citing works

Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures

Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · see citing works

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · see citing works

Alzheimer's disease drug development pipeline: 2019

Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762 · see citing works

History and progress of hypotheses and clinical trials for Alzheimer’s disease

Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723 · see citing works

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease

Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686 · see citing works

The Episodic Memory System: Neurocircuitry and Disorders

Dickerson, B. C., & Eichenbaum, H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.126 · Cited by 660 · see citing works

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643 · see citing works

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634 · see citing works

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628 · see citing works

Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone

Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Fishel, M. A., Kulstad, J. J., Green, P. S., Cook, D. G., et al. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 607 · see citing works

The Alzheimer's disease Beta-secretase enzyme, BACE1

Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550 · see citing works

Randomized trial of verubecestat for prodromal Alzheimer's disease

Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545 · see citing works

Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo

Noble, W. J., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J. L., Gaynor, K., LaFrancois, J. J., Wang, L., Kondo, T., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00259-9 · Cited by 511 · see citing works

The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease

Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495 · see citing works

Clinical uses of intravenous immunoglobulin

Jolles, S. R. A., Sewell, W. A. C., & Misbah, S. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02834.x · Cited by 374 · see citing works

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., RICHTER, R. W., Soininen, H. S., Thein, S., Shiovitz, T. M., Pilcher, G. D., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374 · see citing works

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

May, P. C., Dean, R. A., Lowe, S. L., Martényi, F., Sheehan, S. M., Boggs, L. N., Monk, S. A., Mathes, B. M., Mergott, D. J., Watson, B. M., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3647-11.2011 · Cited by 373 · see citing works

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361 · see citing works

Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease

Mandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355 · see citing works

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

Fleisher, A., Raman, R., Siemers, E., Becerra, L. M., Clark, C. M., Dean, R. A., Farlow, M. R., Galvin, J. E., Peskind, E. R., Quinn, J. F., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1031 · Cited by 332 · see citing works

Reasons for failed trials of disease-modifying treatments for alzheimer disease and their contribution in recent research

Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330 · see citing works

Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer’s Disease

Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166876 · Cited by 329 · see citing works

PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice

Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326 · see citing works

Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis

Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M. W. N., Azzi, M., Lacombe, D., Kong, X., Aman, A. M., Laurin, J., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.015 · Cited by 308 · see citing works

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthé, C., Lent, R. W., Younkin, S. G., Younkin, L. H., Schiff, R. I., & Weksler, M. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305 · see citing works

Tramiprosate in mild-to-moderate Alzheimer's disease — a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295 · see citing works

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 291 · see citing works

Role of RAGE in Alzheimer’s Disease

Cai, Z., Liu, N., Wang, C., Qin, B., Zhou, Y., Xiao, M., Chang, L., Yan, L., & Zhao, B. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0233-3 · Cited by 286 · see citing works

Developing β‐secretase inhibitors for treatment of Alzheimer’s disease

Ghosh, A. K., Brindisi, M., & Tang, J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07476.x · Cited by 272 · see citing works

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258 · see citing works

Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective

Dunn, B., Stein, P., & Cavazzoni, P. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.4607 · Cited by 246 · see citing works

Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease

TCW, J., & Goate, A. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024539 · Cited by 242 · see citing works

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial

Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0607 · Cited by 240 · see citing works

PKC ε Activation Prevents Synaptic Loss, Aβ Elevation, and Cognitive Deficits in Alzheimer's Disease Transgenic Mice

Hongpaisan, J., Sun, M., & Alkon, D. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5209-10.2011 · Cited by 232 · see citing works

A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease

Aisen, P. S. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P. J., & Garceau, D. (2006) · Neurology · doi:10.1212/01.wnl.0000244346.08950.64 · Cited by 201 · see citing works

Neurofibrillary Tangles and Alzheimer’s Disease

Brion, J. (1998) · European Neurology · doi:10.1159/000007969 · Cited by 200 · see citing works

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

Harrington, C. M., Sawchak, S. T., Chiang, C., Davies, J., Donovan, C., Saunders, A. M., Irizarry, M. C., Jeter, B., Zvartau-Hind, M. E., van Dyck, C. H., et al. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391935 · Cited by 198 · see citing works

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

Galasko, D. R., Bell, J. S., Mancuso, J. Y., Kupiec, J. W., Sabbagh, M. N., van Dyck, C. H., Thomas, R. G., Aisen, P. S. S., & Study, F. T. A. D. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000364 · Cited by 187 · see citing works

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

Sabbagh, M. N., Agro, A., Bell, J. S., Aisen, P. S. S., Schweizer, E. E., & Galasko, D. R. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318204b550 · Cited by 161 · see citing works

A phase 3 trial of IV immunoglobulin for Alzheimer disease

Relkin, N. R., Thomas, R. G., Rissman, R. A., Brewer, J. B., Rafii, M. S., van Dyck, C. H., Jack, C. R., Sano, M., Knopman, D. S., Raman, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003904 · Cited by 157 · see citing works

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease

Menting, K. W., & Claassen, J. A. H. R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00165 · Cited by 139 · see citing works

The Experimental Alzheimer’s Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice

Lahiri, D. K., Chen, D., Maloney, B., Holloway, H. W., Yu, Q.-S., Utsuki, T., Giordano, T., Sambamurti, K., & Greig, N. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112102 · Cited by 134 · see citing works

Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology

Fenili, D., Brown, M., Rappaport, R. V., & McLaurin, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0156-7 · Cited by 133 · see citing works

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease

Maia, M., & Sousa, E. (2019) · Pharmaceuticals · doi:10.3390/ph12010041 · Cited by 129 · see citing works

Naturally Occurring Autoantibodies against β-Amyloid: Investigating Their Role in Transgenic Animal andIn VitroModels of Alzheimer's Disease

Dodel, R. C., Balakrishnan, K., Keyvani, K., Deuster, O., Neff, F., Andrei‐Selmer, L., Röskam, S., Stüer, C., Al‐Abed, Y., Noelker, C., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4401-10.2011 · Cited by 127 · see citing works

Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals

Galasko, D. R., Graff‐Radford, N. R., May, S. J., Hendrix, S. B., Cottrell, B. A., Sagi, S. A., MATHER, G. G., Laughlin, M. A., Zavitz, K. H., Swabb, E. A., et al. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815d1048 · Cited by 123 · see citing works

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

Maccecchini, M. L., Chang, M. Y., Pan, C., John, V., Zetterberg, H., & Greig, N. H. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302589 · Cited by 96 · see citing works

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

Farlow, M. R., Thompson, R. E., Wei, L., Tuchman, A. J., Grenier, E., Crockford, D., Wilke, S., Benison, J., & Alkon, D. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180759 · Cited by 82 · see citing works

Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse

Vohora, D., & Bhowmik, M. (2012) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2012.00072 · Cited by 75 · see citing works

Intravenous immunoglobulin and Alzheimer’s disease: what now?

Loeffler, D. A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-70 · Cited by 48 · see citing works

LRP in Alzheimer’s disease: friend or foe?

Ulery, P. G., & Strickland, D. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11455 · Cited by 41 · see citing works

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage

Portelius, E., Dean, R. A., Andréasson, U., Mattsson, N., Westerlund, A., Olsson, M., Demattos, R. B., Racke, M. M., Zetterberg, H., May, P. C., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0075-0 · Cited by 38 · see citing works

Amino Acid Sequence and Structural Comparison of BACE1 and BACE2 Using Evolutionary Trace Method

Mirsafian, H., Ripen, A. M., Merican, A. F., & Mohamad, S. B. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/482463 · Cited by 23 · see citing works

Inhibition of γ-Secretase Leads to an Increase in Presenilin-1

Sogorb‐Esteve, A., García‐Ayllón, M., Llansola, M., Felipo, V., Blennow, K., & Sáez‐Valero, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0705-1 · Cited by 23 · see citing works

Acetylcholinesterase Inhibitors for Alzheimer’s disease: Past, Present, and Potential Future

Truong, B., Quiroz, J. A., & Priefer, R. (2020) · Medical Research Archives · doi:10.18103/mra.v8i12.2271 · Cited by 10 · see citing works

Tramiprosate (Alzhemed) for Alzheimer's disease

Malouf, R. S., & Collins, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007549.pub2 · Cited by 3 · see citing works

The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death

Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 85 · see citing works

A coupled-GAN architecture to fuse MRI and PET image features for multi-stage classification of Alzheimer’s disease

Choudhury, C., Goel, T., & Tanveer, M. (2024) · Information Fusion · doi:10.1016/j.inffus.2024.102415 · Cited by 52 · see citing works

Neurodegenerative Diseases: Can Caffeine Be a Powerful Ally to Weaken Neuroinflammation?

Ruggiero, M., Calvello, R., Porro, C., Messina, G., Cianciulli, A., & Panaro, M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112958 · Cited by 58 · see citing works

Ketogenic diet alleviates cognitive dysfunction and neuroinflammation in APP/PS1 mice via the Nrf2/HO-1 and NF-κB signaling pathways

Jiang, J., Pan, H., Shen, F., Tan, Y., & Chen, S. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373715 · Cited by 50 · see citing works

Neuroinflammation and Neurodegenerative Diseases: How Much Do We Still Not Know?

Balistreri, C. R., & Monastero, R. (2023) · Brain Sciences · doi:10.3390/brainsci14010019 · Cited by 45 · see citing works

Polymer-based nanocarriers to transport therapeutic biomacromolecules across the blood-brain barrier

Romero‐Ben, E., Goswami, U., Soto-Cruz, J., Mansoori-Kermani, A., Mishra, D., Martín‐Saldaña, S., Ugartemendia, J. M., Sosnik, A., Calderón, M., Beloqui, A., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.02.065 · Cited by 46 · see citing works

Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer’s disease

Guo, Q., Li, Y., Xu, S., Wang, P., Qian, K., Yang, P., Sheng, D., Wang, L., Cheng, Y., Meng, R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.074 · Cited by 40 · see citing works

The microbiota–gut–brain axis in mental and neurodegenerative disorders: opportunities for prevention and intervention

Yassin, L. K., Skrabulyte-Barbulescu, J., Alshamsi, S. H., Saeed, S., Alkuwaiti, S. H., Almazrouei, S., Alnuaimi, A., BaniYas, S., Aldhaheri, D., Alderei, M., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1667448 · Cited by 46 · see citing works

Molecular mechanism and therapeutic strategy of bile acids in Alzheimer’s disease from the emerging perspective of the microbiota–gut–brain axis

Wu, M., Cheng, Y., Zhang, R., Han, W., Jiang, H., Bi, C., Zhang, Z., Ye, M., Lin, X., & Liu, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117228 · Cited by 38 · see citing works

From Plaques to Pathways in Alzheimer’s Disease: The Mitochondrial-Neurovascular-Metabolic Hypothesis

Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41 · see citing works

Alzheimer's disease – Where do we go from here?

Борисович, Б. И. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.075 · Cited by 34 · see citing works

Clinical translation of nanomedicines for brain diseases: Current challenges and future directions

Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33 · see citing works

Evaluating the efficacy and safety of Alzheimer’s disease drugs: A meta-analysis and systematic review

Chen, Y., Lai, M., & Tao, M. (2024) · Medicine · doi:10.1097/md.0000000000037799 · Cited by 35 · see citing works

Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer's disease

Wang, Y., Xiong, B., Lin, H., Li, Q., Yang, H., Qiao, Y., Li, Q., Xu, Z., Lyu, W., Qu, W., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114806 · Cited by 32 · see citing works

Preclinical Research on Focused Ultrasound-Mediated Blood–Brain Barrier Opening for Neurological Disorders: A Review

Kong, C., & Chang, W. S. (2023) · Neurology International · doi:10.3390/neurolint15010018 · Cited by 32 · see citing works

Caffeine for Prevention of Alzheimer’s Disease: Is the A2A Adenosine Receptor Its Target?

Merighi, S., Travagli, A., Nigro, M., Pasquini, S., Cappello, M., Contri, C., Varani, K., Vincenzi, F., Borea, P. A., & Gessi, S. (2023) · Biomolecules · doi:10.3390/biom13060967 · Cited by 34 · see citing works

Cerebral organoids with chromosome 21 trisomy secrete Alzheimer’s disease-related soluble aggregates detectable by single-molecule-fluorescence and super-resolution microscopy

Fertan, E., Böken, D., Murray, A., Danial, J. S. H., Lam, J. Y. L., Wu, Y., Goh, P. A., Alić, I., Cheetham, M. R., Lobanova, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02333-3 · Cited by 31 · see citing works

Current therapeutics for Alzheimer’s disease and clinical trials

Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30 · see citing works

A nasally administrated reactive oxygen species-responsive carrier-free gene delivery nanosystem for Alzheimer's disease combination therapy

Chen, Y., Yang, X., Li, J., Luo, H., Huang, Q., Yang, W., Lei, T., Lü, Y., Gong, Q., Li, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113604 · Cited by 30 · see citing works

White matter injury, cholesterol dysmetabolism, and APP/Abeta dysmetabolism interact to produce Alzheimer’s disease (AD) neuropathology: A hypothesis and review

Sharp, F. R., DeCarli, C. S., Jin, L., & Zhan, X. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1096206 · Cited by 30 · see citing works

Curculigoside, a traditional Chinese medicine monomer, ameliorates oxidative stress in Alzheimer's disease mouse model via suppressing ferroptosis

Gong, Y., Wang, Y., Li, Y., Weng, F., Chen, T., & He, L. (2024) · Phytotherapy Research · doi:10.1002/ptr.8152 · Cited by 25 · see citing works

D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer’s disease

Hou, K., Pan, H., Shahpasand‐Kroner, H., Hu, C. J., Abskharon, R. N. N., Seidler, P. M., Mekkittikul, M., Balbirnie, M., Lantz, C., Sawaya, M. R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl2991 · Cited by 25 · see citing works

Discovery of indole-piperazine derivatives as selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting activities and neuroprotective activities

Liang, T., Xie, Z., Dang, B., Wang, J., Zhang, T., Luan, X., Lu, T., Cao, C., & Chen, X. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129148 · Cited by 25 · see citing works

Probiotic Bifidobacterium breve MCC1274 Protects against Oxidative Stress and Neuronal Lipid Droplet Formation via PLIN4 Gene Regulation

Bernier, F., Kuhara, T., & Xiao, J. (2023) · Microorganisms · doi:10.3390/microorganisms11030791 · Cited by 25 · see citing works

Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives

Alrouji, M., Alshammari, M. S., Syed, T., & Shamsi, A. (2025) · Antioxidants · doi:10.3390/antiox14070774 · Cited by 21 · see citing works

Unveiling tomorrow: Carbonic anhydrase activators and inhibitors pioneering new frontiers in Alzheimer's disease

Mishra, K. A., & Sethi, K. K. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400748 · Cited by 21 · see citing works

Positive Allosteric Modulator of SERCA Pump NDC-1173 Exerts Beneficial Effects in Mouse Model of Alzheimer’s Disease

Dahl, R. S., Moore, A. C., Knight, C., Mauger, C., Zhang, H., Schiltz, G. E., Koss, W. A., & Борисович, Б. И. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311057 · Cited by 21 · see citing works

Hyperphosphorylated Tau Inflicts Intracellular Stress Responses that Are Mitigated by Apomorphine

Song, Z., Wang, K., Hagar, H. C., Chen, H., Kuan, C.-Y., Zhang, K., & Kuo, M. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03689-x · Cited by 22 · see citing works

An enquiry to the role of CB1 receptors in neurodegeneration

Fernández‐Moncada, I., Eraso‐Pichot, A., Tor, T. D., Fortunato-Marsol, B., & Marsicano, G. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106235 · Cited by 20 · see citing works

Inflammatory role of S100A8/A9 in the central nervous system non-neoplastic diseases

Tian, Q., Li, Z., Yan, Z., Jiang, S., Zhao, X., Wang, L., & Li, M. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111100 · Cited by 19 · see citing works

Using focused ultrasound to modulate microglial structure and function

Grewal, S., de Andrade, E. G., Kofoed, R. H., Matthews, P. M., Aubert, I., Tremblay, M., & Morse, S. V. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1290628 · Cited by 18 · see citing works

Inflammasome links traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer’s disease

Seplovich, G., Bouchi, Y., Vaccari, J. P. D. R., Pareja, J. C. M., Reisner, A., Blackwell, L. S., Mechref, Y. S., Wang, K., Tyndall, J. A., Tharakan, B., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00107 · Cited by 20 · see citing works

S100A9 protein activates microglia and stimulates phagocytosis, resulting in synaptic and neuronal loss

Pampuščenko, K., Jankevičiūtė, S., Morkūnienė, R., Šulskis, D., Smirnovas, V., Brown, G. C., & Borutaitė, V. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106817 · Cited by 18 · see citing works

Sex-based differences in effector cells of the adaptive immune system during Alzheimer's disease and related dementias

Lutshumba, J., Wilcock, D. M., Monson, N. L., & Stowe, A. M. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106202 · Cited by 19 · see citing works

SERCA pump as a novel therapeutic target for treating neurodegenerative disorders

Dahl, R. S., & Борисович, Б. И. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150748 · Cited by 17 · see citing works

Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer’s disease

Mojarad-Jabali, S., & Roh, K. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125055 · Cited by 17 · see citing works

Donanemab: Not two without a third

Kurkinen, M. T. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/172673 · Cited by 17 · see citing works

Inhibition of CXXC5 function rescues Alzheimer’s disease phenotypes by restoring Wnt/β-catenin signaling pathway

Yoon, M., Kim, H., Shin, H., Lee, H., Kang, M., Park, S., Han, G., Kim, Y. S., & Choi, K. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106836 · Cited by 15 · see citing works

Coffee, antioxidants, and brain inflammation

Rai, S. P., Ansari, A. H., Singh, D., & Singh, S. (2024) · Progress in brain research · doi:10.1016/bs.pbr.2024.06.005 · Cited by 19 · see citing works

Unconventional protein secretion (UPS): role in important diseases

Meldolesi, J. (2023) · Molecular Biomedicine · doi:10.1186/s43556-022-00113-z · Cited by 15 · see citing works

Paradigm shift required for translational research on the brain

Yoon, J. H., Lee, D., Lee, C., Cho, E., Lee, S., Cazenave‐Gassiot, A., Kim, K., Chae, S., Dennis, E. A., & Suh, P. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01218-x · Cited by 14 · see citing works

Ceria nanocluster-based therapy for Alzheimer’s disease through the modulation of activated microglia and attenuation of amyloid-β deposition

Liu, H.-J., Wang, M., Wang, Y., Shi, S., Hu, X., Zhang, D.-B., Fan, D., Mintzer, J., & Xu, P. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100158 · Cited by 13 · see citing works

Network-Medicine-Guided Drug Repurposing for Alzheimer’s Disease: A Multi-Dimensional Systems Pharmacology Approach

Akgüller, Ö., Balcı, M. A., & Cioca, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010003 · Cited by 13 · see citing works

Towards a Unitary Hypothesis of Alzheimer’s Disease Pathogenesis

Área-Gómez, E., & Schon, E. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231318 · Cited by 16 · see citing works

Emerging roles for ITAM and ITIM receptor signaling in microglial biology and Alzheimer's disease‐related amyloidosis

Samuels, J. D., Lukens, J. R., & Price, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15981 · Cited by 13 · see citing works

Targeting Inflammation in Alzheimer’s Disease: Insights Into Pathophysiology and Therapeutic Avenues-A Comprehensive Review

Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 14 · see citing works

MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment

Petrović, N., Essack, M., Sami, A. S., Perry, G. L., Gojobori, T., Isenović, E. R., & Bajić, V. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.107925 · Cited by 12 · see citing works

Enhancing Therapeutic Efficacy of Donepezil, an Alzheimer’s Disease Drug, by Diplazium esculentum (Retz.) Sw. and Its Phytochemicals

Inthachat, W., Chantong, B., Pitchakarn, P., Takoon, C., Karinchai, J., Suttisansanee, U., & Temviriyanukul, P. (2024) · Pharmaceuticals · doi:10.3390/ph17030341 · Cited by 12 · see citing works

Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents

Mạnh, N. V., Hoang, V.-H., Ngo, V. T. H., Kang, S., Jeong, J. J., Ha, H.-J., Kim, H., Kim, Y.-H., Ann, J., & Lee, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114837 · Cited by 12 · see citing works

Recent advances in understanding Alzheimer’s Disease: diagnosis and management strategies

Marín, A., & Budson, A. E. (2023) · Faculty Reviews · doi:10.12703/r/12-24 · Cited by 11 · see citing works

Mitochondria-targeting Cu2-xSe-TPP with dual enzyme activity alleviates Alzheimer's disease by modulating oxidative stress

Wang, L., Yuan, X., Cai, Q., Chen, Y., Jia, Z., Mai, Q., Liu, J., & Liu, Y. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114244 · Cited by 11 · see citing works

MFIFN: A multimodal feature interaction fusion network-based model for Alzheimer’s disease classification

Huang, Y., Liu, J., Li, Z., & Zhang, Q. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.107857 · Cited by 11 · see citing works

Investigating Genetic Overlap between Alzheimer’s Disease, Lipids, and Coronary Artery Disease: A Large-Scale Genome-Wide Cross Trait Analysis

Kirby, A., Porter, T., Adewuyi, E. O., & Laws, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168814 · Cited by 10 · see citing works

Alzheimer’s disease diagnosis from MRI and SWI fused image using self adaptive differential evolutionary RVFL classifier

Goel, T., Verma, S., Tanveer, M., & Suganthan, P. N. (2025) · Information Fusion · doi:10.1016/j.inffus.2024.102917 · Cited by 10 · see citing works

Potential modulation of microglial ferroptosis by Linggui Zhugan decoction in Alzheimer's disease through IL-17 and TNF pathways

Tang, P., Zhao, D., Lin, H., Li, X., Shi, C., Li, P., & Chen, H. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115489 · Cited by 11 · see citing works

Selecting Multitarget Peptides for Alzheimer’s Disease

Kasus‐Jacobi, A., Washburn, J. L., Laurence, R. B., & Pereira, H. A. (2022) · Biomolecules · doi:10.3390/biom12101386 · Cited by 10 · see citing works

Genetic analysis of cognitive preservation in the midwestern Amish reveals a novel locus on chromosome 2

Main, L. R., Song, Y. E., Lynn, A., Laux, R. A., Miskimen, K. L. S., Osterman, M. D., Cuccaro, M. L., Ogrocki, P. K., Lerner, A. J., Vance, J. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14045 · Cited by 9 · see citing works

AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies

Duechs, M. J., Blazevic, D., Rechtsteiner, P., Kenny, C. H., Lamla, T., Low, S. H. H., Savistchenko, J., Neumann, M., Melki, R., Schönberger, T., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00542-9 · Cited by 9 · see citing works

Validation and comparison of virtual reality and 3D mobile games for cognitive assessment against ACE-III in 82 young participants

Bhargava, Y., Kottapalli, A., & Baths, V. (2024) · Scientific Reports · doi:10.1038/s41598-024-75065-1 · Cited by 12 · see citing works

Design and Feasibility Analysis of a Smartphone‐Based Digital Cognitive Assessment Study in the Framingham Heart Study

Sunderaraman, P., Anda‐Duran, I. D., Karjadi, C., Peterson, J. J., Ding, H., Devine, S., Shih, L. C., Popp, Z., Low, S., Hwang, P. H., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031348 · Cited by 8 · see citing works

A Positive Allosteric Modulator of the SERCA Pump Rescues Hippocampal Neuronal Circuits Dysfunction and Cognitive Defects in a Mouse Model of Alzheimer's Disease

Gerasimov, E., Rakovskaya, A., Pchitskaya, E. I., Власова, О. Л., Dahl, R. S., & Борисович, Б. И. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.2337-24.2025 · Cited by 8 · see citing works

Audiogenic Seizures in the Streptozotocin-Induced Rat Alzheimer’s Disease Model

Alves, S. S., de Oliveira, J. A. C., Lazarini-Lopes, W., Servilha‐Menezes, G., Grigório-de-Sant’Ana, M., Vecchio, F. D., Mazzei, R. F., Almeida, S. S., da Silva-Júnior, R. M. P., & Garcia‐Cairasco, N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230153 · Cited by 8 · see citing works

Experience of Youths and Older People With Virtual Reality Games for Cognitive Assessment: Inductive Thematic Analysis and Insights for Key Stakeholders

Bhargava, Y., & Baths, V. (2024) · JMIR XR and spatial computing. · doi:10.2196/59197 · Cited by 8 · see citing works

Nucleosome assembly protein 1-like 5 alleviates Alzheimer’s disease-like pathological characteristics in a cell model

Wang, B. J., Liu, W., & Sun, F.-X. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1034766 · Cited by 8 · see citing works

Unrevealing role of TLRs/NLRP receptors in halting Alzheimer's neuroinflammation: Current progress and existing therapies

Upadhayay, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116285 · Cited by 7 · see citing works

P2Y1 receptor in Alzheimer’s disease

Luo, S., Wang, Y., & Hisatsune, T. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02103 · Cited by 8 · see citing works

Alternative Pharmacological Strategies for the Treatment of Alzheimer’s Disease: Focus on Neuromodulator Function

Cunliffe, G., Lim, Y. T., Chae, W., & Jung, S. (2022) · Biomedicines · doi:10.3390/biomedicines10123064 · Cited by 5 · see citing works

A Comparative Study Using Deep Learning Models And Transfer Learning for Detection And Classification of Alzheimer’s Disease

Dawood, A. S. (2024) · Iraqi Journal of Computer Communication Control and System Engineering · doi:10.33103/uot.ijccce.24.1.5 · Cited by 6 · see citing works

Apolipoprotein E genotype-dependent accumulation of amyloid β in APP-knock-in mouse model of Alzheimer's disease

Takebayashi, Y., Yamazaki, Y., Yamada, H., Yazawa, K., Nakamori, M., Kurashige, T., Morino, H., Takahashi, T., Sotomaru, Y., & Maruyama, H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.10.038 · Cited by 6 · see citing works

Leveraging targeted kinase degradation as a novel therapeutic strategy for Alzheimer's disease

Tassinari, E., & Milelli, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00681c · Cited by 5 · see citing works

Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies

Morgan, D., & Lamb, B. T. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13566 · Cited by 4 · see citing works

Towards a lifelong personalized brain health program: empowering individuals to define, pursue, and monitor meaningful outcomes

Saunders, S., Gomes‐Osman, J., Jannati, A., Ciesla, M. R., Banks, R., Showalter, J., Terrera, G. M., Luz, S. F., Ritchie, C. W., & Pascual‐Leone, Á. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1387206 · Cited by 5 · see citing works

Carnosine Mitigates Cognitive Impairment and Dopamine Release in an Okadaic Acid-Induced Zebrafish Model with Alzheimer’s Disease-like Symptoms

Chern, H., Caruso, G., Desaire, H., & Jarošová, R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00596 · Cited by 6 · see citing works

Bile acids as therapeutic agents

Vu, B., Kawamoto, R., Villalba‐Davila, P., Dong, X., & Karnsakul, W. W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1732854 · Cited by 4 · see citing works

Designed inhibitors to reduce amyloid virulence and cytotoxicity and combat neurodegenerative and infectious diseases

Indig, R. Y., & Landau, M. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2023.102318 · Cited by 7 · see citing works

The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma

Caniceiro, A. B., Agostinho, S. P., Piochi, L. F., Rosário‐Ferreira, N., & Moreira, I. S. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71131 · Cited by 4 · see citing works

Structural correlations between brain magnetic resonance image‐derived phenotypes and retinal neuroanatomy

Sun, Z., Zhang, B., Smith, S. M., Atan, D., Khawaja, A. P., Stuart, K. V., Luben, R., Biradar, M. I., McGillivray, T., Patel, P. J., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16288 · Cited by 4 · see citing works

Sorl1 knockout inhibits expression of brain-derived neurotrophic factor: involvement in the development of late-onset Alzheimer's disease.

Zhao, M., Chen, X., Liu, J., Feng, Y., Wang, C., Xu, T., Liu, W., Liu, X., Liu, M., & Hou, D. (2024) · PubMed Central · doi:10.4103/1673-5374.387975 · Cited by 4 · see citing works

Calcium Signaling and Pathogenesis of Neurodegenerative Disorders: Potential Therapeutic OpportunitiesPreprint

Борисович, Б. И. (2026) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041758 · Cited by 4 · see citing works

Development of Delta Opioid Receptor Antagonists Which Prevent Alzheimer’s Disease-Like Pathology in the 5X-Familial Alzheimer’s Disease [5XFAD] Mouse Model

Tanguturi, P., Mitchell, S., Moukha‐Chafiq, O., Zhang, S., Tillotson, J., Ananthan, S., Augelli‐Szafran, C. E., & Streicher, J. M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00509 · Cited by 3 · see citing works

Chemogenetic Modulation of Astrocytic Activity Rescues Hippocampus Associated Neurodegeneration in Alzheimer's Disease Mice Model 5xFAD

Gerasimov, E., Berg, M., Bolshakova, A., Bezprozvanny, I., & Vlasova, O. (2025) · Journal of Neural Transplantation and Plasticity · doi:10.1155/np/9880933 · Cited by 3 · see citing works

Intranasal delivery of Odorranalectin-modified lipid nanoparticles for multi-targeted therapy of Alzheimer's disease

Zhang, Y., Yin, C., Tian, Y., Li, X., Wang, H., Han, S., Chen, H., & Hou, H. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102764 · Cited by 3 · see citing works

From Molecular Networks to Medicines: Targeting Complexity in Alzheimer’s Disease (AD) Therapy

Kumar, D. R. P., Patel, S., Mishra, P. S., Srivastava, S., Sridhar, S. B., Shareef, J., Sahu, R., Tariq, M., Uddin, J., & Muhsinah, A. B. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05909-6 · Cited by 3 · see citing works

The potential of circulating nonesterified fatty acids and sphingolipids in the biological understanding of cognitive decline and dementia

Moseholm, K. F., Meineche, J. T., & Jensen, M. K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000968 · Cited by 3 · see citing works

Triple-Target Inhibition of Cholinesterase, Amyloid Aggregation, and GSK3β to Ameliorate Cognitive Deficits and Neuropathology in the Triple-Transgenic Mouse Model of Alzheimer’s Disease

He, J., Sun, S., Wang, H., Ying, Z., & Tam, K. Y. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01354-y · Cited by 3 · see citing works

Investigation of the Effects of Acacetin on Autophagy Pathway and Exosome Release in Amyloid Beta Peptide-Induced Toxicity Models

Ercin, N., Beşli, N., Johnson, B. S., Cakmak, R. K., Beker, M., Beker, M. Ç., & Kılıç, Ü. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04908-3 · Cited by 3 · see citing works

Multi-enzyme active CeVO4 nanocubes targetedly reverse apoptosis in AD neurons: Dual pathway mechanism of mitochondrial homeostasis reconstruction and oxidative stress regulation

Wang, L., Cai, Q., Yang, Y., Zhou, Y., Liu, Y., PeiyaoWu, Liu, J., & Liu, J. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.168781 · Cited by 3 · see citing works

Harnessing Passive Pulsatile Shear Stress for Alzheimer’s Disease Prevention and Intervention

Adams, J. A., Uryash, A., & Lopez, J. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231010 · Cited by 3 · see citing works

Lecanemab (Leqembi): an amyloid beta monoclonal antibody approved for the treatment of Alzheimer’s disease

Sang, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00035-2 · Cited by 3 · see citing works

Disease-Modifying Drugs for Alzheimer’s Disease: Bending the Curve

Arshad, F., & Alladi, S. (2025) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_748_25 · Cited by 2 · see citing works

Resource-stratified machine learning framework for cognitive status classification and mild cognitive impairment to dementia progression prediction

Yang, J., Ding, H., Amini, S., Hao, B., Karjadi, C., Au, R., & Paschalidis, I. C. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02006-7 · Cited by 2 · see citing works

Calibrating microglia states in Alzheimer’s disease: decoding immune-metabolic networks and nano-targeted multicomponent therapies

Xing, J. F., Mu, K., Xue, Y., Yang, X., Zhang, D., Gao, W., Zhang, T., Yang, S., Wang, R., Zhang, W., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1843978 · Cited by 2 · see citing works

Trends and hotspots in tea and Alzheimer's disease research from 2014 to 2023: A bibliometric and visual analysis

Meng, X., Cui, W., Liang, Q., Zhang, B., & Wei, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30063 · Cited by 2 · see citing works

A Pilot Study to Research Associations between Alzheimer’s Disease and Suicide: The Questionnaire FeasibilityPreprint

Rodrigues, J. F. R., Rodrigues, L. P., da Silva, K. C. A., Rubatino, F. V. M., Fischer, H., Rodrigues, F. C. P., Júnior, E. G., Barbosa, P. M. K., Payão, S. L. M., de Godoy, M. F., et al. (2024) · Preprints.org · doi:10.20944/preprints202405.1144.v1 · Cited by 2 · see citing works

Cascaded Multimodal Deep Learning in the Differential Diagnosis, Progression Prediction, and Staging of Alzheimer’s and Frontotemporal DementiaPreprint

Guarnier, G., Reinelt, J. D., Molloy, E. N., Mihai, P. G., Einaliyan, P., Valk, S. L., Modestino, A. E., Ugolini, M., Mueller, K., Wu, Q., et al. (2024) · medRxiv · doi:10.1101/2024.09.23.24314186 · Cited by 2 · see citing works

Constructing a prognostic risk model for Alzheimer’s disease based on ferroptosis

Wang, X., Zhai, R.-Q., Li, Z., Li, H.-Q., Lei, Y.-T., Zhao, F.-F., Hao, X.-X., Wang, S., & Wu, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1168840 · Cited by 1 · see citing works

Urinary formic acid is associated with cerebral amyloid deposition and glucose metabolism in memory clinic patients

Wang, Y., Zhu, L., He, K., Cui, L., Pan, F., Guan, Y., He, R., Xie, F., & Guo, Q. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241309117 · Cited by 1 · see citing works

A Novel Brain-Targeting Nanoparticle Loaded with Biatractylolide and Its Protective Effect on Alzheimer’s Disease

Hu, Q., Liu, C., Tan, J., Wang, J., Yang, H., Liu, Y., Mao, H., Jiang, Z., Feng, X., & Tao, X. (2025) · Pharmaceuticals · doi:10.3390/ph18060809 · Cited by 1 · see citing works

Chimeric Antigen Receptor Cell Therapy: Current Status and Its Potential in Aging and Alzheimer’s Disease

Jurcău, M. C., Iovanovici, D. C., Jurcău, A., Militaru, M., Udrea, R. B., Comanescu, A. D., & Nunkoo, V. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189009 · Cited by 2 · see citing works

Breaking the Alzheimer’s Treatment Stalemate: Synergistic Application Strategies of Nanomaterials and Pharmaceutical Agents

Gao, H., Cheng, F., Zhang, Z., Yan, B., Liao, P., Zhang, S., Li, D., Chen, F., & Lei, P. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05320-7 · Cited by 1 · see citing works

Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy

Oxford, A. E., Stewart, E. S., & Rohn, T. T. (2020) · International Journal of Alzheimer s Disease · doi:10.1155/2020/5380346 · Cited by 109 · see citing works

Paths to Precision Medicine for Alzheimer's Disease: A Systematic Review

Dieguez, D., Jr. (2021) · DigitalCommons@UNMC

Clinical trials of new drugs for Alzheimer disease

Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702 · see citing works

Effective drug therapy for Alzheimer’s disease remains elusive

Traynor, K. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/news150026 · Cited by 5 · see citing works

Why do so many clinical trials of therapies for Alzheimer's disease fail?

Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32399-1 · Cited by 228 · see citing works